Helicore Bio uses a proprietary antibody‑peptide conjugate platform to create long‑acting obesity and cardiometabolic therapies that can be administered quarterly or less frequently. By linking stable, biased GLP‑1 agonist or selective amylin agonist peptides to a GIP ligand‑binding antibody, the company delivers potent metabolic drugs with extended systemic exposure and demonstrated Phase 1 safety.
Funding
$65M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
2OFounders
Product
Problem
Obesity and cardiometabolic diseases often require frequent injections of peptide therapeutics, leading to low patient adherence, high treatment burden, and suboptimal clinical outcomes.
Solution
Helicore Bio addresses this challenge with a proprietary antibody‑peptide conjugate platform that links therapeutic peptides to a long‑acting GIP ligand‑binding antibody. The platform enables the creation of stable, biased GLP‑1 agonist and selective amylin agonist conjugates that retain potency while extending systemic exposure. By leveraging the antibody’s durability, the resulting medicines can be administered quarterly or less frequently, reducing injection frequency for patients. Phase 1 clinical data demonstrate clean safety, tolerability, and durable target engagement of the GIP antibody component, supporting the feasibility of the long‑acting approach. The platform is modular, allowing rapid generation of multiple metabolic candidates from a single backbone.
Target Audience
Primary customers are biopharmaceutical companies developing obesity and cardiometabolic therapies, as well as clinicians seeking long‑acting treatment options for patients with metabolic disease.
Features
- GIP ligand‑binding antibody with first‑in‑class safety and durable target engagement validated in Phase 1
- Proprietary library of biased, stable GLP‑1 receptor agonist peptides engineered for potency and conjugate stability
- Proprietary library of selective amylin receptor agonist peptides with tunable AMY1R/AMY3R selectivity
- Antibody‑peptide conjugation technology that preserves peptide activity while extending half‑life to enable quarterly dosing
- Modular platform that supports rapid development of multiple metabolic therapeutics from a single antibody backbone